Neuren Pharmaceuticals Limited (NEU.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
1.9900-0.0100 (-0.50%)
At close: 4:10PM AEDT
| Previous close | 2.0000 |
| Open | 1.9750 |
| Bid | 1.9750 x 1214500 |
| Ask | 1.9900 x 938700 |
| Day's range | 1.9600 - 2.0000 |
| 52-week range | 0.9950 - 2.5300 |
| Volume | 29,378 |
| Avg. volume | 159,434 |
| Market cap | 256.642M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1090 |
| Earnings date | 24 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Great news for Neuren Pharmaceuticals Limited (ASX:NEU): Insiders acquired stock in large numbers last year
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
- Simply Wall St.
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- PR Newswire
Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials
Neuren Pharmaceuticals Limited (ASX: NEU) has received clear and constructive guidance from the FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes. All three syndromes are serious neurological disorders that emerge in early childhood and have no approved medicines.
© 2021 Verizon Media. All rights reserved.
